Shamis & Gentile, P.A. is investigating claims on behalf of investors of Telix Pharmaceuticals Ltd. (“Telix” or the “Company”) (NASDAQ: TLX). Impacted investors are advised to contact the firm now.
The investigation concerns whether Telix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. Telix’s disclosures regarding the development of its prostate cancer therapeutic candidates are currently under focus.
On July 22, 2025, the Company announced it had received a subpoena from the U.S. Securities and Exchange Commission (“SEC”) seeking documents and information related to its disclosures about these programs.
Following this announcement, Telix’s stock experienced a significant decline. On July 23, 2025, the next trading day, TLX American Depository Shares fell approximately 10.3% from about $16.28 to around $14.60 per share. Intraday, the shares dropped as much as 16.4% to multi-month lows, ultimately closing down roughly 12.4% for the day.
Analysts also noted the investigation could impact the Company’s value and cut their price targets accordingly.
Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise, and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.
Attorney advertising. Prior results do not guarantee similar outcomes.
